For HER2+ breast cancer, the monoclonal antibody Herceptin (trastuzumab) is a primary therapeutic option, targeting HER2 and inhibiting cancer cell growth through mechanisms such as the disruption of HER2 homodimerization [18,19,20]. This evidence concerns the gene ERBB2 and breast cancer.